These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 10680050

  • 21. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y, Shapiro MD.
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [Abstract] [Full Text] [Related]

  • 22. Fibrate therapy in patients with metabolic syndrome and diabetes mellitus.
    Dayspring T, Pokrywka G.
    Curr Atheroscler Rep; 2006 Sep; 8(5):356-64. PubMed ID: 16901405
    [Abstract] [Full Text] [Related]

  • 23. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy.
    Fazio S, Linton MF.
    Curr Atheroscler Rep; 2004 Mar; 6(2):148-57. PubMed ID: 15023300
    [Abstract] [Full Text] [Related]

  • 24. The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
    Schonfeld G.
    Atherosclerosis; 1994 Dec; 111(2):161-74. PubMed ID: 7718018
    [Abstract] [Full Text] [Related]

  • 25. Fibrates after the FIELD study: Some answers, more questions.
    Wierzbicki AS.
    Diab Vasc Dis Res; 2006 Dec; 3(3):166-71. PubMed ID: 17160911
    [Abstract] [Full Text] [Related]

  • 26. A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
    Steiner G.
    Treat Endocrinol; 2005 Dec; 4(5):311-7. PubMed ID: 16185099
    [Abstract] [Full Text] [Related]

  • 27. Diabetic dyslipidemia.
    Kreisberg RA.
    Am J Cardiol; 1998 Dec 17; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [Abstract] [Full Text] [Related]

  • 28. Hypertriglyceridemia and the fibrate trials.
    Faergeman O.
    Curr Opin Lipidol; 2000 Dec 17; 11(6):609-14. PubMed ID: 11086334
    [Abstract] [Full Text] [Related]

  • 29. Fibrates and microvascular complications in diabetes--insight from the FIELD study.
    Ansquer JC, Foucher C, Aubonnet P, Le Malicot K.
    Curr Pharm Des; 2009 Dec 17; 15(5):537-52. PubMed ID: 19199980
    [Abstract] [Full Text] [Related]

  • 30. Combination therapy of statins and fibrates in the management of cardiovascular risk.
    Fiévet C, Staels B.
    Curr Opin Lipidol; 2009 Dec 17; 20(6):505-11. PubMed ID: 19829109
    [Abstract] [Full Text] [Related]

  • 31. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.
    Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg MJ.
    Am J Med; 2009 Oct 17; 122(10):962.e1-8. PubMed ID: 19698935
    [Abstract] [Full Text] [Related]

  • 32. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M, Roberts A, Davies S, Rees A.
    Drugs; 2004 Oct 17; 64(11):1181-96. PubMed ID: 15161326
    [Abstract] [Full Text] [Related]

  • 33. Current, new and future treatments in dyslipidaemia and atherosclerosis.
    Chong PH, Bachenheimer BS.
    Drugs; 2000 Jul 17; 60(1):55-93. PubMed ID: 10929930
    [Abstract] [Full Text] [Related]

  • 34. Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
    Brinton EA.
    Curr Atheroscler Rep; 2008 Feb 17; 10(1):25-32. PubMed ID: 18366982
    [Abstract] [Full Text] [Related]

  • 35. [Favorable effects of decreasing lipids in patients with diabetes mellitus].
    Gouni-Berthold I, Krone W.
    Dtsch Med Wochenschr; 2006 Dec 17; 131 Suppl 8():S252-4. PubMed ID: 17139581
    [Abstract] [Full Text] [Related]

  • 36. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L, Szostak WB.
    Eur J Clin Pharmacol; 1991 Dec 17; 40(1):33-41. PubMed ID: 2060543
    [Abstract] [Full Text] [Related]

  • 37. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B, Maes M, Zambon A.
    Nat Clin Pract Cardiovasc Med; 2008 Sep 17; 5(9):542-53. PubMed ID: 18628776
    [Abstract] [Full Text] [Related]

  • 38. Fibrates: no ACCORD on their use in the treatment of dyslipidaemia.
    Wierzbicki AS.
    Curr Opin Lipidol; 2010 Aug 17; 21(4):352-8. PubMed ID: 20625256
    [Abstract] [Full Text] [Related]

  • 39. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
    Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD.
    Diabetes Care; 1998 Apr 17; 21(4):641-8. PubMed ID: 9571357
    [Abstract] [Full Text] [Related]

  • 40. Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations.
    Hamilton-Craig I, Kostner KM, Woodhouse S, Colquhoun D.
    Int J Evid Based Healthc; 2012 Sep 17; 10(3):181-90. PubMed ID: 22925614
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.